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INTRODUCTION 
 
Cell motility, such as smooth muscle contraction and cell migration, is 
controlled by the reversible phosphorylation of the regulatory light chain of myosin II 
and other cytoskeletal proteins. Mounting evidence suggests that in smooth muscle cells 
and other types of cells in vertebrates, myosin phosphatase (MP) plays an important role 
in controlling the phosphorylation of myosin II as well as other cytoskeletal proteins, 
including ezrin, moesin, and radixin.1 MP is a holoenzyme consisting of a catalytic 
subunit of a type-1 Ser/Thr phosphatase (PP1C) delta isoform, a myosin phosphatase 
targeting subunit 1 (MYPT1), and an accessory subunit M21. In this ternary complex, 
MYPT1 is responsible for regulating the phosphatase activity.1  
A recent X-ray crystallographic study revealed an allosteric interaction 
between PP1C and the N-terminal ankyrin repeat domain of MYPT1 that confers the 
substrate specificity of the enzyme.2 MP activity is suppressed when Thr696 or Thr853 of 
MYPT1 is phosphorylated by various kinases, such as ROCK, ZIPK, ILK, and PAK.1,3 
However, it is still unclear how the phosphorylation of MYPT1 inhibits MP activity. 
The amino acid sequence around Thr696 of MYPT1 is highly conserved among MYPT1 
family members including MYPT2 and MBS85. Therefore, structural insights into the 
inhibitory domain of MYPT1 are expected to provide new clues to fully elucidate the 
mechanism that controls phosphatase activity via the phosphorylation of MYPT1 or 
other family members involved in kinase-phosphatase crosstalk in cytoskeletal 
regulation.  
 Here, we prepared a bacterial recombinant fragment of MYPT1 
corresponding to residues 658 to 714, including the phosphorylation site Thr696, and 
determined its three-dimensional structure through the use of computer-assisted distance 
geometry and a simulated annealing protocol combined with stable-isotope-aided 
multi-dimensional NMR techniques.  
 
 
MATERIALS AND METHODS 
 
Molecular cloning and NMR sample preparation 
 Protein preparation was performed using a previously reported method.4 
Briefly, the cDNA fragment encoding the 57-residue peptide corresponding to residues 
658 to 714 of human MYPT1 was cloned into a modified pET30 vector that produces 
His x6 fusion protein with a PreScission protease recognition site.5 The protein was 
uniformly labeled with 15N or doubly labeled with 15N and 13C by over-expression in E. 
coli grown in minimal media containing 15NH4Cl and/or 13C-glucose. Purification was 
carried out using a chelating His-tag column. The fused tag was cleaved using 
PreScission protease during dialysis in the buffer for the NMR sample. The protein 
includes three extra amino acid residues Gly-Pro-Met at the N-terminus. 
 
NMR spectroscopy 
 The NMR samples consisted of ~1 mM protein, 20 mM sodium phosphate, 
100 mM sodium chloride, and 0.03 % NaN3. The solvent contained 10 or 100 % D2O 
for NMR locking, and the pH of the solution was measured directly with a pH meter 
and adjusted to 6.0. All NMR experiments were performed on a Varian INOVA 750 
MHz spectrometer with a 5 mm 1H{13C/15N} triple-resonance probe containing a Z-axis 
gradient coil.6 During the NMR experiments, the sample temperature was maintained at 
10.0 °C. For backbone resonance assignments, we recorded 1H-15N HSQC, HNCA, 
CBCA(CO)NH, and HNCACB spectra.7 To assign the resonances of the side chains, 
C(CO)NH, H(CCO)NH, 15N-edited TOCSY, and HCCH-TOCSY spectra were 
recorded.7,8 To obtain distance information, we measured 15N-edited NOESY, 13C-edited 
NOESY, and 1H-1H 2D-NOESY spectra.7,8 Homonuclear 2D-NOESY, 13C-edited 
NOESY, and HCCH-TOCSY were obtained with the sample dissolved in D2O. All NOE 
experiments were acquired using a 150 ms mixing time. The NMR data were processed 
and displayed by NMRPipe.9 The processed NMR spectra were displayed and analyzed 
by Sparky.10 
 Structural calculation 
 A total of 527 independent unambiguous NOE peaks were selected and used 
as inputs in the calculation of the structure together with 86 TALOS dihedral angle 
restraints.11 Additionally, 62 hydrogen bond restraints based on the secondary structure 
were used in the calculation. The calculation was executed using the simulated 
annealing protocol sa.inp in XPLOR-NIH version 2.050.12 The 20 lowest energy 
structures were selected from the final calculations for 100 structures. The 20 structures 
had no distance or angle violations. The quality of the structures was analyzed by 
Procheck-NMR.13 The structures were also displayed and analyzed by MOLMOL.14  
 
 
RESULTS AND DISCUSSION 
 
 Previous reports have shown that the thiophosphorylated MYPT1 C-terminal 
fragment and the MBS85 fragment including the inhibitory phosphorylation site inhibit 
isolated PP1C activity.4,5 Indeed, our preliminary study suggests that when the 
57-residue MYPT1 fragment containing Thr696 (MYPT1(658-714)) is phosphorylated, it 
inhibits the activity of MP purified from smooth muscle cells as well as the activity of 
the enzyme associated with cytoskeletons in skinned smooth muscle fibers.5 The amino 
acid sequence is shown in Figure 1(A).  
We prepared the NMR-active stable-isotope-labeled peptide of this fragment, 
MYPT1(658-714), by using an Escherichia coli over-expression system. The uniformly 
15N- and doubly 13C/15N-labeled peptides were subjected to a series of NMR 
experiments that are described in the Materials and Methods section. The 1H-15N HSQC 
spectra were acquired at various temperatures (10, 15, 20, 25, and 30 °C) and pH values 
(4.4, 5.8, and 7.3) in order to optimize the conditions. At 10 °C and pH 6.0, 
MYPT1(658-714) displayed 1H-15N HSQC spectra with excellent cross-peak dispersion, 
as shown in Figure 1(B). The number of peaks as well as their intensities and line 
shapes suggest that MYPT1(658-714) exists in a single conformation under these 
conditions, and as a result, all NMR measurements were performed under these 
optimized conditions. 
The detailed procedures used for resonance assignment and structural 
calculation are described in the Materials and Methods section. Extensive NMR data 
analysis resulted in resonance assignments for all of the 1HN, 1Hα, 13Cα, and 15N 
resonances in the peptide backbone and for more than 95 % of the 1H resonances of the 
side chains. Finally, 527 NOE peaks, 62 hydrogen bonds, and 86 angle constraints were 
employed in the structural calculation. Figure 1(C) shows overlaid images of the 20 
lowest energy models obtained from the structural calculation. Statistics describing 
these 20 structures are shown in Table 1. The stereo-chemical quality of the structures 
was analyzed by the Procheck-NMR method. In total, 97.0 % of all amino acid residues 
were found in either the fully allowed or partially allowed region of the Ramachandran 
plot. 
As shown at the bottom of Figure 1(C), the average structure of 
MYPT1(658-714) is relatively extended and consists of three helices. The helices 
correspond to residues 658-668 (helix A), 673-696 (helix B), and 703-710 (helix C). 
The structure of each helical region is well converged among the 20 models with 
backbone RMSD values of 0.35 +/- 0.09 (helix A), 0.86 +/- 0.22 (helix B), and 0.33 +/- 
0.10 Å (helix C). Helices A and B, and helices B and C are connected by short loop 
regions corresponding to residues 669-673 and 697-701, respectively. The short loop 
comprising residues 669-673 that connects helices A and B contains a Pro residue at 
position 672. The resonance of Pro672 13Cγ appears at relatively low field, 27.4 ppm, and 
the peaks of Thr671 and Val673 are sharp and clear in the 1H-15N HSQC plot (Figure 1(B)). 
Moreover, the NOE cross peaks of the α1H of Thr671 and the two protons in the 
δ position of Pro672 were detected in the 13C-edited NOESY spectrum, as shown in 
Figure 2. Hence, we concluded that Pro672 is in the trans conformation and not in a 
cis-trans equilibrium state.17,18  
The orientation of the three helices was not defined in this structural study. As 
shown in Table 1, few long-range NOE signals were observed and were insufficient to 
determine the overall structure. One possibility of such an ill-defined structure is that 
the lack of long-range NOE signals is due to the extended molecular shape. Another 
possibility is that the two loop regions have a degree of flexibility that prevents the 
convergence of the solution structure. To address this issue, residual dipolar coupling 
constants (RDCs) can provide useful information.19 Thus, we attempted to prepare 
samples for these NMR experiments. However, this was unsuccessful due to unexpected 
interactions between the MYPT1 fragment and the co-solute, pf1-phage. Therefore, 
another approach, {1H}-15N heteronuclear NOE spectroscopy, was used to obtain 
information about the dynamics  (Figure 3).20 The loop regions show relatively small 
values of the peak intensity ratio (NOEon / NOEoff) compared to the three helical regions, 
which indicates the existence of higher flexibility in the loop regions. Thus, the overall 
structure of MYPT1(658-714) is variable due to the flexibility of the inter-helical angle.  
 The phosphorylation site Thr696 is located at the C-terminal end of helix B. 
The structural plasticity of the loop region connecting helix B and C is possibly required 
for recognition by kinases, such as ROCK, ZIPK, ILK, and PAK. The helical structure 
of the MYPT1 inhibitory domain is similar to the structure of the autoinhibitory 
mechanism of calcineurin (CaN).21 As shown in the crystal structure of the inactive 
form of CaN without calmodulin, the α-helical autoinhibitory domain directly docks at 
the active site of CaN.22 Thus, it is possible that the flexibility of the loop structure of 
MYPT1(658-714) detected in this work provides accessibility to the catalytic center of 
MP. Figure 4 illustrates the hypothetical surface structure colored by electrostatic 
potential. Importantly, positively charged residues including Arg682, Arg687, and Arg690 
are present in helix B, and hydrophobic side chains including Val699, Leu701, and Leu704 
are clustered in helix C. As predicted from the crystal structure of the MP catalytic 
domain,2 these basic and hydrophobic regions have the potential to form 
complementary interactions with the acidic and hydrophobic grooves of the active site 
of MP. However, no information regarding the local structure around the Thr696 
phosphorylation site was obtained. Nonetheless, it is possible that the flexibility of the 
inter-helical angle of the MYPT1(658-714) fragment in solution is analogous to the 
motion of the intact MP at the phosphorylation site. The present NMR structural study 
of the model peptide revealed residues that potentially play important roles in the 
phosphorylation of Thr696 and in the inhibition of MP that is necessary for cytoskeletal 
regulation in cells. Further functional and structural studies of intact MP with full-length 
MYPT1 as well as a study on a fragment of MYPT1 including Thr853 are currently 
being undertaken by our group. 
 
 
Coordinates of the 20 structures and resonance assignments were deposited in PDB 
(2kjy) and BMRB (16346), respectively. 
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FIGURE LEGENDS 
 
Figure 1. Overview of MYPT1(658-714) solution structure. (A) Amino acid 
sequence of MYPT1(658-714). (B) 1H-15N HSQC spectrum of MYPT1(658-714). 
Each peak is labeled with amino acid type and residue number. Phosphorylation site, 
Thr696, is labeled with red letters. Signals from the tag sequence at the N-terminus are 
labeled with asterisk. (C) Backbone traces of the 20 lowest energy structures 
obtained via structural calculation. From top to bottom, three structures drawn as 
wire models are superimposed on helices A, B, and C. The ribbon model is depicted 
using an averaged and energy-minimized coordinate. Only the Thr696 side chain is 
illustrated as a ball-and-stick model. Starting and ending residues of helices are 
labeled with amino acid type and residue number. (D) {1H}-15N heteronuclear NOE 
results plotted versus residue numbers of MYPT1(658-714). Orange bars indicate 
helical regions. (E) Surface potential of MYPT1(658-714). Blue and red indicate 
positively and negatively charged areas, respectively. 
 
 
 
 
SUPPLIMENTARY MATERIALS 
 
Figure S1. Strip plot of 13C-edited NOESY of MYPT1(658-714). Alpha proton of 
Thr671 has NOEs with delta protons of Pro672, suggesting that Pro672 is in the trans 
conformation.  
 
 
  
 
 
 
 
 
 
 
Table 1. Summary of restraints and statistics of the final 20 structures of 
MYPT1(658-714).  
RMSD to the mean structure (Å)  
   Region T659 - S668 R674 - T696 T702 - T709 
   Backbone 0.35 + 0.09 0.86 + 0.22 0.33 + 0.10 
   All heavy atoms 1.64 + 0.14 1.82 + 0.22 1.30 + 0.20 
Unambiguous restraints  
   Intraresidue NOEs     235 
   Sequential NOEs     177 
   Medium-range NOEs (1 < |i - j| < 4)     113 
   Long-range NOEs (|i - j| > 5)       2 
   Hydrogen bond restraints      62 
   TALOS angle restraints      86 
   Total number of structural restraints     675 
Experimental restraint violations  
   Distances with violations > 0.3 Å       0 
   Dihedral angles with violations > 5 Å       0 
X-PLOR energy terms (kcal/mol)  
   Eoverall  96.5985 + 1.1496 
   Ebonds   4.4920 + 0.1677 
   Eangles  69.2550 + 0.6868 
   Eimproper   2.2584 + 0.9245 
   Evdw  10.1468 + 1.3369 
   Enoe   0.3381 + 0.0741 
   Ecdih  10.1093 + 0.1743 
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